New Alzheimer’s Treatment Shows Real Promise in Slowing Cognition Decline Using Antibody in Human Trials
[ad_1] Leading pharmaceutical company Eli Lilly has just demonstrated the efficacy of its drug donanemab for Alzheimer’s disease in phase 2 human clinical trials. The results are a major advance in treating a disease that currently affects six million Americans, but has almost no methods of relief. Alzheimer’s is caused by the accumulation of tau…